Originally developed for the treatment of B-cell malignancies [49,50], rituximab demonstrated clinical activity in RA, leading to its subsequent approval in moderate to severe RA with inadequate response to TNF antagonists. This evidence concerns the gene TNF and rheumatoid arthritis.